tris(2-hydroxypropyl)ammonium salicylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tris(2-hydroxypropyl)ammonium salicylate
• 英文别名: 1-[Bis(2-hydroxypropyl)amino]propan-2-ol;2-hydroxybenzoic acid；1-[bis(2-hydroxypropyl)amino]propan-2-ol;2-hydroxybenzoic acid
• 化学式: C₇H₆O₃*C₉H₂₁NO₃
• 分子量: 329.393
• InChiKey: IFBQYIDZQOBKLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.52
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  122
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  三异丙醇胺 、 水杨酸 以 甲醇 为溶剂， 反应 2.0h， 以90%的产率得到tris(2-hydroxypropyl)ammonium salicylate
  参考文献：
  名称：

  三（2-羟丙基）铵基质子离子液体和质子熔融盐的合成，晶体结构和性能

  摘要：

  首先通过质子从羧酸到三（2-羟丙基）胺的直接反应合成了十五种三（2-羟丙基）铵盐（TPA盐）。合成的TPA盐的组成和结构通过NMR（1 H，13C），FT-IR光谱和元素分析。通过单晶X射线衍射研究了水杨酸，烟酸和丙二酸盐中三（2-羟丙基）铵阳离子的晶体结构和构象。热稳定性研究表明，TPA盐是熔融温度低于100°C的质子离子液体或室温离子液体或熔融盐。研究了选定的TPA盐对细菌和真菌菌株的抗菌活性。此外，它是示出了用于第一次合成TPA盐可以用作潜在的缓冲剂为68 Ga的放射性标记的双官能螯合剂（BCA）和临床上相关的肽（的PSMA-11，PSMA-617，DOTA-NOC， DOTA-TATE）。

  DOI：

  10.1016/j.molliq.2020.114717

文献信息

• Composition for Patch Preparation Comprising Drug, Organic Solvent, Lipophilic Mass Base, and Powder
  申请人：MEDRX CO., LTD.

  公开号：US20150174249A1

  公开（公告）日：2015-06-25

  The present disclosure provides a composition for a non-aqueous patch preparation with excellent adhesibility which can sustainedly release a drug. The patch preparation can improve the adhesibility of the patch preparation and the release property of a drug by the addition of a powder ingredient the long-time sustention of the adhesibility of tape preparations enables an improvement of the transdermal absorbability and the sustained release of a drug.

  本公开提供了一种具有良好粘附性和可持续释放药物的非水性贴剂制剂组合物。通过添加粉末成分，该贴剂制剂可以改善贴剂制剂的粘附性和药物的释放性能，贴剂制剂的长时间粘附性能有助于提高经皮吸收性和药物的持续释放。
• ADHESIVE PREPARATION COMPOSITION OBTAINED BY BLENDING DRUG, ORGANIC SOLVENT, LIPOPHILIC OINTMENT BASE, AND POWDER
  申请人：Medrx Co., Ltd.

  公开号：EP2865376A1

  公开（公告）日：2015-04-29

  The object of the present invention is to provide a composition for a non-aqueous patch preparation with excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility of the patch preparation and the release property of a drug by the addition of a powder ingredient (a filler or the like). As a result, the long-time sustention of the adhesibility of tape preparations enables an improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous parch preparation of the present invention, and thereby a preparation with the improved transdermal absorbability and the improved sustained release can prepared.

  本发明的目的是提供一种可持续释放药物的非水贴剂组合物，该组合物具有极佳的粘附性。本发明的贴片制剂可以通过添加粉末成分（填料或类似物）来改善贴片制剂的粘附性和药物释放性能。因此，长期保持贴片制剂的粘附性可以提高药物的透皮吸收性和持续释放性。通过使用包含这种粉末成分的贴片制剂组合物，将药物（无论药物类型）溶解在有机溶剂或离子液体中，制备出包含有机溶剂的药物溶液，然后将药物溶液加入到本发明的非水基贴片制剂中，从而制备出具有改善的透皮吸收性和改善的持续释放性的制剂。
• NOVEL BASE COMPOSITION FOR TAPE AGENT
  申请人：MEDRx Co., Ltd.

  公开号：EP3045166A1

  公开（公告）日：2016-07-20

  The object of the present invention is to provide a composition for a non-aqueous patch preparation having an excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility thereof as well as the release property of a drug by the addition of powder ingredient (e.g. a filler). As a result, the long-time sustention of the adhesibility of patch preparations can achieve the improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal-absorbability and sustained release can prepared.

  本发明的目的是提供一种用于非水贴剂制备的组合物，该组合物具有极佳的粘附性，可持续释放药物。 本发明的贴剂制剂可以通过添加粉末成分（如填充剂）来提高其粘附性以及药物释放性能。因此，长期保持贴片制剂的粘附性可以提高药物的透皮吸收性和持续释放性。通过使用包含这种粉末成分的贴剂制剂组合物，将药物（无论药物类型）溶解在有机溶剂或离子液体中，制备出包含有机溶剂的药物溶液，将药物溶液加入到本发明的非水贴剂制剂中，从而制备出具有改善的透皮吸收性和持续释放性的制剂。
• NOVEL COMPOSITION FOR PLASTER BASE MATERIAL IN TAPE PREPARATION
  申请人：MEDRx Co., Ltd.

  公开号：EP3824883A1

  公开（公告）日：2021-05-26

  The present invention relates to a composition for a non-aqueous patch preparation comprising a drug, an organic solvent, and a powder which is insoluble both in the organic solvent and in a lipophilic plaster base material, wherein the organic solvent comprises a fatty acid-based ionic liquid and/or a salicylic acid-based ionic liquid, the powder is light anhydrous silicic acid, and the powder for an adhesive layer is contained as shown in the following inequality: 0.2×the weight of the adhesive layer×the bulk density of the powder≤the amount of the powder to be added≤0.6×the weight of the adhesive layer×the tap density of the powder.

  本发明涉及一种用于非水贴剂制备的组合物，该组合物由药物、有机溶剂和既不溶于有机溶剂又不溶于亲脂性石膏基质材料的粉末组成，其中有机溶剂包括脂肪酸基离子液体和/或水杨酸基离子液体，粉末为轻质无水硅酸，用于粘合层的粉末的含有量如下不等式所示：0.2×粘合剂层的重量×粉末的体积密度≤粉末的添加量≤0.6×粘合剂层的重量×粉末的自重密度。
• Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder
  申请人：MEDRX CO., LTD.

  公开号：US10543275B2

  公开（公告）日：2020-01-28

  The present disclosure provides a composition for a non-aqueous patch preparation with excellent adhesibility which can sustainedly release a drug. The patch preparation can improve the adhesibility of the patch preparation and the release property of a drug by the addition of a powder ingredient the long-time sustention of the adhesibility of tape preparations enables an improvement of the transdermal absorbability and the sustained release of a drug.

  本公开提供了一种用于非水贴剂的组合物，该贴剂具有良好的粘附性，可持续释放药物。通过添加粉末成分，贴片制剂可以提高贴片制剂的粘附性和药物的释放性能，长期保持胶带制剂的粘附性可以提高药物的透皮吸收性和持续释放性。